Snakebite drug discovery: high-throughput screening to identify novel snake venom metalloproteinase toxin inhibitors.

ABSTRACT: Snakebite envenoming results in ∼100,000 deaths per year, with close to four times as many victims left with life-long sequelae. Current antivenom therapies have several limitations including high cost, variable cross-snake species efficacy and a requirement for intravenous administration in a clinical setting. Next-generation snakebite therapies are being widely investigated with the aim to improve cost, efficacy, and safety. In recent years several small molecule drugs have shown considerable promise for snakebite indication, with oral bioavailability particularly promising for community delivery rapidly after a snakebite. However, only two such drugs have entered clinical development for snakebite. To offset the risk of attrition during clinical trials and to better explore the chemical

SUBMITTER: Clare RH 

PROVIDER: S-EPMC10808794 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature